Unlocking The Potential of IGHV3-76 as A Cancer Vaccine (G28406)

Target Name: IGHV3-76

NCBI ID: G28406

IGHV3-76

Other Name(s): Immunoglobulin heavy variable 3-76 (pseudogene) | immunoglobulin heavy variable 3-76 (pseudogene) | 3-76P | IGHV376

Unlocking The Potential of IGHV3-76 as A Cancer Vaccine

IGHV3-76, also known as Immunoglobulin heavy variable 3-76 (pseudogene), is a single-chain variable region antibody that is found in the human body. It is a type of immunoglobulin that is made by B cells, which are a type of immune cell in the body.

IGHV3-76 is a protein that is made up of four constant genes, which are the same throughout the molecule. It is one of the proteins that is found in the humoral system, which is the system that helps the body to fight off infections.

One of the unique features of IGHV3-76 is its structure. It is made up of four monomers, which are the same sequence of amino acids that are always present in each monomer. This is different from other proteins, which are typically made up of multiple polypeptides, which are different sequences of amino acids.

The IGHV3-76 protein has been studied for many years, and researchers have identified its unique features as well as its potential as a drug target. One of the main reasons for studying IGHV3-76 is its potential as a cancer vaccine.

CarbonatedImmunoglobulin heavy variable 3-76 (pseudogene), a potential cancer vaccine, has been shown to stimulate an adaptive T cell response against a variety of cancer antigens, including self- antigens, in both humans and animals.

IGHV3-76 has also been shown to have anti-tumor activity in a variety of models, including the treatment of cancer cells in culture and in animal models. Additionally, IGHV3-76 has been shown to have the potential to be used in combination with other cancer vaccines to enhance its anti-tumor effects.

Another potential use for IGHV3-76 as a drug target is its role in the development of autoimmune diseases. IGHV3-76 has been shown to play a role in the development of autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis.

Research has also shown that IGHV3-76 may have the potential to be used as a biomarker for monitoring the effectiveness of cancer treatments. By measuring the levels of IGHV3-76 in the body, researchers can determine how well an individual is responding to a particular treatment and tailor their treatment accordingly.

IGHV3-76 has also been shown to have the potential to be used as a potential therapeutic agent for a variety of diseases. For example, IGHV3-76 has been shown to have anti-inflammatory effects, which may make it a useful agent for the treatment of a variety of inflammatory diseases.

In conclusion, IGHV3-76 is a protein that is made up of four monomers and is found in the humoral system. It has been studied for many years and has potential as a cancer vaccine, anti-tumor activity, and as a biomarker for monitoring the effectiveness of cancer treatments. Further research is needed to fully understand the potential of IGHV3-76 as a drug target and its potential as a therapeutic agent for a variety of diseases.

Protein Name: Immunoglobulin Heavy Variable 3-76 (pseudogene)

The "IGHV3-76 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-76 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets